| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6070578 | Journal of the American Academy of Dermatology | 2014 | 7 Pages |
Abstract
This rare variant of CD30+ PCFCL needs be distinguished from CD30+ aggressive B-cell lymphomas. CD30 in this variant of CBCLs may serve as a therapeutic target for anti-CD30 antibody-based strategies.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Werner MD, Dmitry V. MD, PhD, Arno MD, Rudolf A. MD, PhD, Petr MD, Veronika MD, Katrin MD, Reinhard MD, Stephan MD, Dieter R. PhD, Marianne MD,